CAI Stock Analysis: Buy, Sell, or Hold?
CAI - Caris Life Sciences, Inc. Common Stock
$17.31
-1.16 (-6.28%)
▼
5d:
-3.67%
30d:
+10.25%
90d:
-5.98%
BUY
MODERATE Confidence
Analysis Updated: Jun 22, 2026 12:00 AM ET
Earnings: Aug 11, 2026
Get Alerted When CAI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: CAI shows positive signals but monitor for confirmation. Market pricing in 0.9% decline. Moderate conviction.
💡 BUY OPPORTUNITY: CAI shows positive signals but monitor for confirmation. Market pricing in 0.9% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$17.80
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$11.05
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: CAI is currently trading at $17.31, which is considered slightly high relative to its 30-day fair value range of $15.41 to $17.63. The stock's valuation (Forward PE: 47.3) is in line with its historical norms (48.7). Remarkably, the market is currently pricing in an annual earnings decline of 0.9% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, CAI is in a downtrend. Immediate support is located at $15.78, while resistance sits at $18.79. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: CAI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $27.83 (+60.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, CAI is in a downtrend. Immediate support is located at $15.78, while resistance sits at $18.79. Short-term momentum is weak, with the stock down 6.3% recently.
Market Sentiment: CAI has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $27.83 (+60.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$15.41 -
$17.63
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
71.4%
All Signals
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-6.3%)
- BULLISH: Trading 60.8% below Wall St target ($27.83)
Trading Range Analysis
30-Day Trading Range
$15.41 -
$17.63
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$15.78
Resistance Level
$18.79
Current Trend
Downtrend
Technical data as of
Jun 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
47.33
Wall Street Target
$27.83
(+60.8%)
Revenue Growth (YoY)
78.8%
Profit Margin
3.8%
Valuation Discount vs History
-0.9% cheaper
PE vs Historical
47.3 vs 48.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.9%
(market-implied from PE analysis)
1-Year Target
$17.15
(-1%)
2-Year Target
$17.00
(-2%)
3-Year Target
$16.85
(-3%)
3-Yr Target (if PE normalizes)
(PE: 47→49)
$17.33
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 47.3, Growth: 175.2%)
$58.42
(+238%)
Base:
(SPY PE: 21.8, Growth: 175.2%)
$26.88
(+55%)
Bear:
(PE: 18.5, Growth: 175.2%)
$22.85
(+32%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 47.3 to 48.7
Stabilization Target:
$17.81
(+2.9%)
PE Expansion Potential:
+2.9%
Share & Embed Analysis
Last updated: June 23, 2026 6:57 AM ET
Data refreshes hourly during market hours. Next update: 7:57 AM
Data refreshes hourly during market hours. Next update: 7:57 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is CAI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1022 | 64 BUY |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$197 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 55 HOLD |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$105 | 56 HOLD |